Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88044977 |
LAW OFFICE ASSIGNED |
LAW OFFICE 110 |
MARK SECTION |
MARK |
TURN THERAPEUTICS |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
TURN THERAPEUTICS |
OWNER SECTION |
NAME |
Global Health Solutions LLC |
STREET |
5959 Topanga Canyon Blvd. 170 |
CITY |
Woodland Hills |
STATE |
California |
ZIP/POSTAL CODE |
91302 |
COUNTRY |
United States |
PHONE |
706-844-1025 |
EMAIL |
XXXX |
owner-curr AUTHORIZED TO COMMUNICATE VIA E-MAIL |
Yes |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused
lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparations and
substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia,
obesity and cognitive disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for skin care;
Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and
diabetes; Pharmaceutical preparations for the treatment and prevention of infectious diseases; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical
preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic
rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating skin disorders; Pharmaceutical
preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical
preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, antivirals;
Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and
preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks;
Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for
the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical skin lotions; Analgesic and muscle relaxant pharmaceutical preparations; Antibacterial pharmaceuticals;
Balms for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for infectious diseases; Dermatological pharmaceutical products; Drug delivery agents
consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Ocular pharmaceuticals; Plant extracts for pharmaceutical purposes |
GOODS OR SERVICES |
KEEP ALL LISTED |
INTERNATIONAL CLASS |
042 |
CURRENT IDENTIFICATION |
Development of pharmaceutical preparations and medicines; Research and development in the pharmaceutical and biotechnology fields; Research on
the subject of pharmaceuticals; Testing of pharmaceuticals |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
1 |
ALLOWANCE MAIL DATE |
01/08/2019 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
2 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
250 |
TOTAL AMOUNT |
250 |
SIGNATURE SECTION |
SIGNATURE |
/Miya Yusa/ |
SIGNATORY'S NAME |
Miya Yusa |
SIGNATORY'S POSITION |
Associate Attorney, Polsinelli LLP, California bar member |
DATE SIGNED |
07/05/2019 |
FILING INFORMATION |
SUBMIT DATE |
Fri Jul 05 19:52:20 EDT 2019 |
TEAS STAMP |
USPTO/ESU-XXX.XXX.XXX.X-2
0190705195220800795-88044
977-62055d730c7612684a15d
92264ce2292936c65d45ebd2f
cd031dfb1251e9167ebb6-DA-
2560-20190705194417651712 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: TURN THERAPEUTICS
SERIAL NUMBER: 88044977
The applicant, Global Health Solutions LLC, having an address of
5959 Topanga Canyon Blvd. 170
Woodland Hills, California 91302
United States
706-844-1025
XXXX (authorized)
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 01/08/2019.
For International Class 005:
Current identification: Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic
preparations and substances; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparations and substances for the treatment of
damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders;
Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the
prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical
preparations for the treatment and prevention of infectious diseases; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of
immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma;
Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for
treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely,
a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products
and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy
blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products for
ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and
infectious diseases, for the treatment of cancer; Pharmaceutical skin lotions; Analgesic and muscle relaxant pharmaceutical preparations; Antibacterial pharmaceuticals; Balms for pharmaceutical
purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for infectious diseases; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that
facilitate delivery of a wide range of pharmaceuticals; Ocular pharmaceuticals; Plant extracts for pharmaceutical purposes
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
For International Class 042:
Current identification: Development of pharmaceutical preparations and medicines; Research and development in the pharmaceutical and biotechnology fields; Research on the subject of pharmaceuticals;
Testing of pharmaceuticals
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the first extension request.
A fee payment in the amount of $250 will be submitted with the form, representing payment for 2 classes.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /Miya Yusa/ Date Signed: 07/05/2019
Signatory's Name: Miya Yusa
Signatory's Position: Associate Attorney, Polsinelli LLP, California bar member
RAM Sale Number: 88044977
RAM Accounting Date: 07/08/2019
Serial Number: 88044977
Internet Transmission Date: Fri Jul 05 19:52:20 EDT 2019
TEAS Stamp: USPTO/ESU-XXX.XXX.XXX.X-2019070519522080
0795-88044977-62055d730c7612684a15d92264
ce2292936c65d45ebd2fcd031dfb1251e9167ebb
6-DA-2560-20190705194417651712